Bipolar DisorderOLF-BPNCT06809881

OLFACTION AND BIPOLAR DISODER

A study testing olfactory testing, MRI acquisition, clinical assessment in people with Bipolar Disorder, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

To compare olfactory performance between patients with BD and HC and correlate their performances to neuroimaging data Read more about this study

Who is it for?: Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for: Bipolar Disorder
What is being tested?: olfactory testing, MRI acquisition, clinical assessment
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 240 participants
Where: 1 siteFrance
Study dates: 1 Jan 2016to 1 Jan 2020
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

Patients with BD and HC
Fluent in french
Having a public health insurance
Not being on tutorship

Who cannot join

Family history of bipolar disorder for controls
Alcohol dependence

Trial locations and contacts

1 site in 1 country.

France1 site

Inserm U 955 Eq 15
Créteil, VAL DE MARNE, 94000

Other trials in France

About this study

To compare olfactory performance between patients with BD and HC and correlate their performances to neuroimaging data

Conditions: Bipolar Disorder
Being tested: olfactory testing, MRI acquisition, clinical assessment
Medical subject headings: Bipolar Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

olfactory testing, MRI acquisition, clinical assessmentOther

Study groups in NCT06809881
Study group	Role	What they receive
Controls	Other	n= 40 Healthy subjects Receives: Other: olfactory testing, MRI acquisition, clinical assessment
Patients	Other	n=100 Patients with bipolar disorder Receives: Other: olfactory testing, MRI acquisition, clinical assessment

What is being measured

The primary outcome is the main question the study is designed to answer.

Olfactive performance
Testing of olfactory performance (odor threshold, odor discrimination, odor identification)
Measured: through study completion, an average of 4 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Jan 20161 Jan 2020

First posted5 Feb 2025
Study start1 Jan 2016
Primary completion1 Jan 2020
Study completion1 Jan 2020

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (5)Papers the sponsor has linked to this study.
Other trials for Bipolar DisorderStudies of the same condition, open and under way.
More trials run by Institut National de la Santé Et de la Recherche Médicale, FranceThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Basic science
Allocation: Non-randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 240 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06809881
Sponsor's protocol ID: C15-06
Acronym: OLF-BP
Status last verified: Feb 2019
First submitted: 22 Dec 2017
Last updated: 2 Sep 2025
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Undecided

Publications

Bauer M, Glenn T, Achtyes ED, Alda M, Agaoglu E, Altinbas K, Andreassen OA, Angelopoulos E, Ardau R, Vares EA, Aydin M, Ayhan Y, Baethge C, Bauer R, Baune BT, Balaban C, Becerra-Palars C, Behere AP, Behere PB, Belete H, Belete T, Belizario GO, Bellivier F, Belmaker RH, Benedetti F, Berk M, Bersudsky Y, Bicakci S, Birabwa-Oketcho H, Bjella TD, Brady C, Cabrera J, Cappucciati M, Castro AMP, Chen WL, Cheung EYW, Chiesa S, Crowe M, Cuomo A, Dallaspezia S, Del Zompo M, Desai P, Dodd S, Donix M, Etain B, Fagiolini A, Fellendorf FT, Ferensztajn-Rochowiak E, Fiedorowicz JG, Fountoulakis KN, Frye MA, Geoffroy PA, Gonzalez-Pinto A, Gottlieb JF, Grof P, Haarman BCM, Harima H, Hasse-Sousa M, Henry C, Hoffding L, Houenou J, Imbesi M, Isometsa ET, Ivkovic M, Janno S, Johnsen S, Kapczinski F, Karakatsoulis GN, Kardell M, Kessing LV, Kim SJ, Konig B, Kot TL, Koval M, Kunz M, Lafer B, Landen M, Larsen ER, Lenger M, Lewitzka U, Licht RW, Lopez-Jaramillo C, MacKenzie A, Madsen HO, Madsen SAKA, Mahadevan J, Mahardika A, Manchia M, Marsh W, Martinez-Cengotitabengoa M, Martiny K, Mashima Y, McLoughlin DM, Meesters Y, Melle I, Meza-Urzua F, Ming MY, Monteith S, Moorthy M, Morken G, Mosca E, Mozzhegorov AA, Munoz R, Mythri SV, Nacef F, Nadella RK, Nakanotani T, Nielsen RE, O'Donovan C, Omrani A, Osher Y, Ouali U, Pantovic-Stefanovic M, Pariwatcharakul P, Petite J, Pfennig A, Ruiz YP, Pilhatsch M, Pinna M, Pompili M, Porter R, Quiroz D, Rabelo-da-Ponte FD, Ramesar R, Rasgon N, Ratta-Apha W, Ratzenhofer M, Redahan M, Reddy MS, Reif A, Reininghaus EZ, Richards JG, Ritter P, Rybakowski JK, Sathyaputri L, Scippa AM, Simhandl C, Severus E, Smith D, Smith J, Stackhouse PW Jr, Stein DJ, Stilwell K, Strejilevich S, Su KP, Subramaniam M, Sulaiman AH, Suominen K, Tanra AJ, Tatebayashi Y, Teh WL, Tondo L, Torrent C, Tuinstra D, Uchida T, Vaaler AE, Veeh J, Vieta E, Viswanath B, Yoldi-Negrete M, Yalcinkaya OK, Young AH, Zgueb Y, Whybrow PC. Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder. Int J Bipolar Disord. 2021 Sep 1;9(1):26. doi: 10.1186/s40345-021-00231-7.
PubMed 34467430
Favre P, Pauling M, Stout J, Hozer F, Sarrazin S, Abe C, Alda M, Alloza C, Alonso-Lana S, Andreassen OA, Baune BT, Benedetti F, Busatto GF, Canales-Rodriguez EJ, Caseras X, Chaim-Avancini TM, Ching CRK, Dannlowski U, Deppe M, Eyler LT, Fatjo-Vilas M, Foley SF, Grotegerd D, Hajek T, Haukvik UK, Howells FM, Jahanshad N, Kugel H, Lagerberg TV, Lawrie SM, Linke JO, McIntosh A, Melloni EMT, Mitchell PB, Polosan M, Pomarol-Clotet E, Repple J, Roberts G, Roos A, Rosa PGP, Salvador R, Sarro S, Schofield PR, Serpa MH, Sim K, Stein DJ, Sussmann JE, Temmingh HS, Thompson PM, Verdolini N, Vieta E, Wessa M, Whalley HC, Zanetti MV, Leboyer M, Mangin JF, Henry C, Duchesnay E, Houenou J; ENIGMA Bipolar Disorder Working Group. Widespread white matter microstructural abnormalities in bipolar disorder: evidence from mega- and meta-analyses across 3033 individuals. Neuropsychopharmacology. 2019 Dec;44(13):2285-2293. doi: 10.1038/s41386-019-0485-6. Epub 2019 Aug 21.
PubMed 31434102
Sarrazin S, Poupon C, Teillac A, Mangin JF, Polosan M, Favre P, Laidi C, D'Albis MA, Leboyer M, Lledo PM, Henry C, Houenou J. Higher in vivo Cortical Intracellular Volume Fraction Associated with Lithium Therapy in Bipolar Disorder: A Multicenter NODDI Study. Psychother Psychosom. 2019;88(3):171-176. doi: 10.1159/000498854. Epub 2019 Apr 5.
PubMed 30955011
Nunes A, Schnack HG, Ching CRK, Agartz I, Akudjedu TN, Alda M, Alnaes D, Alonso-Lana S, Bauer J, Baune BT, Boen E, Bonnin CDM, Busatto GF, Canales-Rodriguez EJ, Cannon DM, Caseras X, Chaim-Avancini TM, Dannlowski U, Diaz-Zuluaga AM, Dietsche B, Doan NT, Duchesnay E, Elvsashagen T, Emden D, Eyler LT, Fatjo-Vilas M, Favre P, Foley SF, Fullerton JM, Glahn DC, Goikolea JM, Grotegerd D, Hahn T, Henry C, Hibar DP, Houenou J, Howells FM, Jahanshad N, Kaufmann T, Kenney J, Kircher TTJ, Krug A, Lagerberg TV, Lenroot RK, Lopez-Jaramillo C, Machado-Vieira R, Malt UF, McDonald C, Mitchell PB, Mwangi B, Nabulsi L, Opel N, Overs BJ, Pineda-Zapata JA, Pomarol-Clotet E, Redlich R, Roberts G, Rosa PG, Salvador R, Satterthwaite TD, Soares JC, Stein DJ, Temmingh HS, Trappenberg T, Uhlmann A, van Haren NEM, Vieta E, Westlye LT, Wolf DH, Yuksel D, Zanetti MV, Andreassen OA, Thompson PM, Hajek T; ENIGMA Bipolar Disorders Working Group. Using structural MRI to identify bipolar disorders - 13 site machine learning study in 3020 individuals from the ENIGMA Bipolar Disorders Working Group. Mol Psychiatry. 2020 Sep;25(9):2130-2143. doi: 10.1038/s41380-018-0228-9. Epub 2018 Aug 31.
PubMed 30171211
Hibar DP, Westlye LT, Doan NT, Jahanshad N, Cheung JW, Ching CRK, Versace A, Bilderbeck AC, Uhlmann A, Mwangi B, Kramer B, Overs B, Hartberg CB, Abe C, Dima D, Grotegerd D, Sprooten E, Boen E, Jimenez E, Howells FM, Delvecchio G, Temmingh H, Starke J, Almeida JRC, Goikolea JM, Houenou J, Beard LM, Rauer L, Abramovic L, Bonnin M, Ponteduro MF, Keil M, Rive MM, Yao N, Yalin N, Najt P, Rosa PG, Redlich R, Trost S, Hagenaars S, Fears SC, Alonso-Lana S, van Erp TGM, Nickson T, Chaim-Avancini TM, Meier TB, Elvsashagen T, Haukvik UK, Lee WH, Schene AH, Lloyd AJ, Young AH, Nugent A, Dale AM, Pfennig A, McIntosh AM, Lafer B, Baune BT, Ekman CJ, Zarate CA, Bearden CE, Henry C, Simhandl C, McDonald C, Bourne C, Stein DJ, Wolf DH, Cannon DM, Glahn DC, Veltman DJ, Pomarol-Clotet E, Vieta E, Canales-Rodriguez EJ, Nery FG, Duran FLS, Busatto GF, Roberts G, Pearlson GD, Goodwin GM, Kugel H, Whalley HC, Ruhe HG, Soares JC, Fullerton JM, Rybakowski JK, Savitz J, Chaim KT, Fatjo-Vilas M, Soeiro-de-Souza MG, Boks MP, Zanetti MV, Otaduy MCG, Schaufelberger MS, Alda M, Ingvar M, Phillips ML, Kempton MJ, Bauer M, Landen M, Lawrence NS, van Haren NEM, Horn NR, Freimer NB, Gruber O, Schofield PR, Mitchell PB, Kahn RS, Lenroot R, Machado-Vieira R, Ophoff RA, Sarro S, Frangou S, Satterthwaite TD, Hajek T, Dannlowski U, Malt UF, Arolt V, Gattaz WF, Drevets WC, Caseras X, Agartz I, Thompson PM, Andreassen OA. Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. Mol Psychiatry. 2018 Apr;23(4):932-942. doi: 10.1038/mp.2017.73. Epub 2017 May 2.
PubMed 28461699

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bipolar Disorder Type I With Mania
RecruitingPhase 2
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
Bipolar I Disorder
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
Bipolar-I Disorder With Mania or Mania With Mixed Features
Enrolling by invitation
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
Schizophrenia Disorder, Schizoaffective Disorder
RecruitingPhase 3
Pramipexole vs Placebo Treatment in Bipolar Disorder With Anhedonic Depression
Bipolar Disorder (BD)

All Bipolar Disorder trials

Study at a glance

From the registry record, last updated by the sponsor on 2 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: OLFACTION AND BIPOLAR DISODER
ClinicalTrials.gov ID: NCT06809881
Acronym / sponsor ID: OLF-BP / C15-06
Conditions: Bipolar Disorder
Study type: Interventional
Recruitment status: Completed
Enrolment: 240 participants (actual)
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, FranceOther government
Study start: 1 Jan 2016 (actual)
Primary completion: 1 Jan 2020 (actual)
Study completion: 1 Jan 2020 (actual)
First posted: 5 Feb 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

To compare olfactory performance between patients with BD and HC and correlate their performances to neuroimaging data

Study design

Primary purpose: Basic science
Allocation: Non-randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Controls	Other	Other: olfactory testing, MRI acquisition, clinical assessmentn= 40 Healthy subjects
Patients	Other	Other: olfactory testing, MRI acquisition, clinical assessmentn=100 Patients with bipolar disorder

Who may qualify

Ages: 18 to 65 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (4 listed)

Patients with BD and HC
Fluent in french
Having a public health insurance
Not being on tutorship

Key exclusion criteria (2 listed)

Family history of bipolar disorder for controls
Alcohol dependence

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
olfactory testing, MRI acquisition, clinical assessment	Other	Controls, Patients

Primary outcome

Olfactive performance
Time frame: through study completion, an average of 4 years
Testing of olfactory performance (odor threshold, odor discrimination, odor identification)

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2025.
Results publication: PubMed 34467430Bauer M, Glenn T, Achtyes ED, Alda M, Agaoglu E, Altinbas K, Andreassen OA, Angelopoulos E, Ardau R, Vares EA, Aydin M, Ayhan Y, Baethge C, Bauer R, Baune BT, Balaban C, Becerra-Palars C, Behere AP, Behere PB, Belete H, Belete T, Belizario GO, Bellivier F, Belmaker RH, Benedetti F, Berk M, Bersudsky Y, Bicakci S, Birabwa-Oketcho H, Bjella TD, Brady C, Cabrera J, Cappucciati M, Castro AMP, Chen WL, Cheung EYW, Chiesa S, Crowe M, Cuomo A, Dallaspezia S, Del Zompo M, Desai P, Dodd S, Donix M, Etain B, Fagiolini A, Fellendorf FT, Ferensztajn-Rochowiak E, Fiedorowicz JG, Fountoulakis KN, Frye MA, Geoffroy PA, Gonzalez-Pinto A, Gottlieb JF, Grof P, Haarman BCM, Harima H, Hasse-Sousa M, Henry C, Hoffding L, Houenou J, Imbesi M, Isometsa ET, Ivkovic M, Janno S, Johnsen S, Kapczinski F, Karakatsoulis GN, Kardell M, Kessing LV, Kim SJ, Konig B, Kot TL, Koval M, Kunz M, Lafer B, Landen M, Larsen ER, Lenger M, Lewitzka U, Licht RW, Lopez-Jaramillo C, MacKenzie A, Madsen HO, Madsen SAKA, Mahadevan J, Mahardika A, Manchia M, Marsh W, Martinez-Cengotitabengoa M, Martiny K, Mashima Y, McLoughlin DM, Meesters Y, Melle I, Meza-Urzua F, Ming MY, Monteith S, Moorthy M, Morken G, Mosca E, Mozzhegorov AA, Munoz R, Mythri SV, Nacef F, Nadella RK, Nakanotani T, Nielsen RE, O'Donovan C, Omrani A, Osher Y, Ouali U, Pantovic-Stefanovic M, Pariwatcharakul P, Petite J, Pfennig A, Ruiz YP, Pilhatsch M, Pinna M, Pompili M, Porter R, Quiroz D, Rabelo-da-Ponte FD, Ramesar R, Rasgon N, Ratta-Apha W, Ratzenhofer M, Redahan M, Reddy MS, Reif A, Reininghaus EZ, Richards JG, Ritter P, Rybakowski JK, Sathyaputri L, Scippa AM, Simhandl C, Severus E, Smith D, Smith J, Stackhouse PW Jr, Stein DJ, Stilwell K, Strejilevich S, Su KP, Subramaniam M, Sulaiman AH, Suominen K, Tanra AJ, Tatebayashi Y, Teh WL, Tondo L, Torrent C, Tuinstra D, Uchida T, Vaaler AE, Veeh J, Vieta E, Viswanath B, Yoldi-Negrete M, Yalcinkaya OK, Young AH, Zgueb Y, Whybrow PC. Variations in seasonal solar insolation are associated with a history of suicide attempts in bipolar I disorder. Int J Bipolar Disord. 2021 Sep 1;9(1):26. doi: 10.1186/s40345-021-00231-7.
Results publication: PubMed 31434102Favre P, Pauling M, Stout J, Hozer F, Sarrazin S, Abe C, Alda M, Alloza C, Alonso-Lana S, Andreassen OA, Baune BT, Benedetti F, Busatto GF, Canales-Rodriguez EJ, Caseras X, Chaim-Avancini TM, Ching CRK, Dannlowski U, Deppe M, Eyler LT, Fatjo-Vilas M, Foley SF, Grotegerd D, Hajek T, Haukvik UK, Howells FM, Jahanshad N, Kugel H, Lagerberg TV, Lawrie SM, Linke JO, McIntosh A, Melloni EMT, Mitchell PB, Polosan M, Pomarol-Clotet E, Repple J, Roberts G, Roos A, Rosa PGP, Salvador R, Sarro S, Schofield PR, Serpa MH, Sim K, Stein DJ, Sussmann JE, Temmingh HS, Thompson PM, Verdolini N, Vieta E, Wessa M, Whalley HC, Zanetti MV, Leboyer M, Mangin JF, Henry C, Duchesnay E, Houenou J; ENIGMA Bipolar Disorder Working Group. Widespread white matter microstructural abnormalities in bipolar disorder: evidence from mega- and meta-analyses across 3033 individuals. Neuropsychopharmacology. 2019 Dec;44(13):2285-2293. doi: 10.1038/s41386-019-0485-6. Epub 2019 Aug 21.
Results publication: PubMed 30955011Sarrazin S, Poupon C, Teillac A, Mangin JF, Polosan M, Favre P, Laidi C, D'Albis MA, Leboyer M, Lledo PM, Henry C, Houenou J. Higher in vivo Cortical Intracellular Volume Fraction Associated with Lithium Therapy in Bipolar Disorder: A Multicenter NODDI Study. Psychother Psychosom. 2019;88(3):171-176. doi: 10.1159/000498854. Epub 2019 Apr 5.
Results publication: PubMed 30171211Nunes A, Schnack HG, Ching CRK, Agartz I, Akudjedu TN, Alda M, Alnaes D, Alonso-Lana S, Bauer J, Baune BT, Boen E, Bonnin CDM, Busatto GF, Canales-Rodriguez EJ, Cannon DM, Caseras X, Chaim-Avancini TM, Dannlowski U, Diaz-Zuluaga AM, Dietsche B, Doan NT, Duchesnay E, Elvsashagen T, Emden D, Eyler LT, Fatjo-Vilas M, Favre P, Foley SF, Fullerton JM, Glahn DC, Goikolea JM, Grotegerd D, Hahn T, Henry C, Hibar DP, Houenou J, Howells FM, Jahanshad N, Kaufmann T, Kenney J, Kircher TTJ, Krug A, Lagerberg TV, Lenroot RK, Lopez-Jaramillo C, Machado-Vieira R, Malt UF, McDonald C, Mitchell PB, Mwangi B, Nabulsi L, Opel N, Overs BJ, Pineda-Zapata JA, Pomarol-Clotet E, Redlich R, Roberts G, Rosa PG, Salvador R, Satterthwaite TD, Soares JC, Stein DJ, Temmingh HS, Trappenberg T, Uhlmann A, van Haren NEM, Vieta E, Westlye LT, Wolf DH, Yuksel D, Zanetti MV, Andreassen OA, Thompson PM, Hajek T; ENIGMA Bipolar Disorders Working Group. Using structural MRI to identify bipolar disorders - 13 site machine learning study in 3020 individuals from the ENIGMA Bipolar Disorders Working Group. Mol Psychiatry. 2020 Sep;25(9):2130-2143. doi: 10.1038/s41380-018-0228-9. Epub 2018 Aug 31.
Results publication: PubMed 28461699Hibar DP, Westlye LT, Doan NT, Jahanshad N, Cheung JW, Ching CRK, Versace A, Bilderbeck AC, Uhlmann A, Mwangi B, Kramer B, Overs B, Hartberg CB, Abe C, Dima D, Grotegerd D, Sprooten E, Boen E, Jimenez E, Howells FM, Delvecchio G, Temmingh H, Starke J, Almeida JRC, Goikolea JM, Houenou J, Beard LM, Rauer L, Abramovic L, Bonnin M, Ponteduro MF, Keil M, Rive MM, Yao N, Yalin N, Najt P, Rosa PG, Redlich R, Trost S, Hagenaars S, Fears SC, Alonso-Lana S, van Erp TGM, Nickson T, Chaim-Avancini TM, Meier TB, Elvsashagen T, Haukvik UK, Lee WH, Schene AH, Lloyd AJ, Young AH, Nugent A, Dale AM, Pfennig A, McIntosh AM, Lafer B, Baune BT, Ekman CJ, Zarate CA, Bearden CE, Henry C, Simhandl C, McDonald C, Bourne C, Stein DJ, Wolf DH, Cannon DM, Glahn DC, Veltman DJ, Pomarol-Clotet E, Vieta E, Canales-Rodriguez EJ, Nery FG, Duran FLS, Busatto GF, Roberts G, Pearlson GD, Goodwin GM, Kugel H, Whalley HC, Ruhe HG, Soares JC, Fullerton JM, Rybakowski JK, Savitz J, Chaim KT, Fatjo-Vilas M, Soeiro-de-Souza MG, Boks MP, Zanetti MV, Otaduy MCG, Schaufelberger MS, Alda M, Ingvar M, Phillips ML, Kempton MJ, Bauer M, Landen M, Lawrence NS, van Haren NEM, Horn NR, Freimer NB, Gruber O, Schofield PR, Mitchell PB, Kahn RS, Lenroot R, Machado-Vieira R, Ophoff RA, Sarro S, Frangou S, Satterthwaite TD, Hajek T, Dannlowski U, Malt UF, Arolt V, Gattaz WF, Drevets WC, Caseras X, Agartz I, Thompson PM, Andreassen OA. Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. Mol Psychiatry. 2018 Apr;23(4):932-942. doi: 10.1038/mp.2017.73. Epub 2017 May 2.
Individual participant dataSharing planned: Undecided

Related trials for Bipolar Disorder

RecruitingPhase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bipolar Disorder Type I With Mania
RecruitingPhase 2
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
Bipolar I Disorder
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
Bipolar-I Disorder With Mania or Mania With Mixed Features
Enrolling by invitation
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
Schizophrenia Disorder, Schizoaffective Disorder
RecruitingPhase 3
Pramipexole vs Placebo Treatment in Bipolar Disorder With Anhedonic Depression
Bipolar Disorder (BD)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Olfactive performance (time frame: through study completion, an average of 4 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06809881, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2025; AzTrials last refreshed its copy on 27 Oct 2026.